Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
845 results about "Glioma" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A tumor that originates in the glial cells of the brain or spinal cord.
Use of CDK inhibitor for the treatment of glioma
ActiveUS8946226B2Prevent proliferationReduce molecular weightOrganic active ingredientsOrganic chemistryGlioblastomaCytotoxicity
Owner:NERVIANO MEDICAL SERVICES SRL
Pyrvinium For The Treatment of Cancer
InactiveUS20090099062A1Promote degradationImprove stabilityBiocideOrganic active ingredientsDiseaseNon cancer
The present invention concerns a pyrvinium compound or an analog thereof for the treatment of cancers. This compound inhibits Wnt activity in the cells of cancers such as adrenocortical, hepatocellular, hepatoblastoma, malignant melanoma, ovarian, Wilm's tumor, Barrett's esophageal, glioma, bladder, breast, gastric, head & neck, lung cell, mesothelioma, and cervical cancers. The present invention also provides a method for assaying for compounds that alter Wnt pathway activity. Also provided are methods for treating Wnt-related non-cancer disease states.
Owner:VANDERBILT UNIV
Method for Diagnosing, Prognosing and Treating Glioma
InactiveUS20070141066A1Long median patient survivalShort overall survivalHeavy metal active ingredientsCompound screeningAbnormal tissue growthAnti mitotic
The invention provides generally a method of monitoring, diagnosing, prognosing and treating glioma. Specifically, the invention provides for three (3) prognostic subclasses of glioma, which are differentially associated with activation of the akt and notch signaling pathways. Tumor displaying neural or proneural PN lineage markers (including notch pathway elements) show longer median patient survival, while the two remaining tumor markers Prolif and Mes are associated with shortened survival. Tumors classified in this manner may also be treated with the appropriate PN- Prolif- or Mes-therapeutic corresponding to the subclassification in combination with anti-mitotic agents, anti-angiogenic agents, Akt antagonists, and neural differentiation agents. Alternatively, the invention also provides for method of prognosing and diagnosing glioma with a two-gene model based on the expression levels of PTEN and DLL3.
Owner:GENENTECH INC
Prognostic and diagnostic method for cancer therapy
InactiveUS20090170715A1Sugar derivativesMicrobiological testing/measurementTherapy resistantCancers diagnosis
The present invention provides novel methods and kits for diagnosing the presence of cancer within a patient, and for determining whether a subject who has cancer is susceptible to different types of treatment regimens. The cancers to be tested include, but are not limited to, prostate, breast, lung, gastric, ovarian, bladder, lymphoma, mesothelioma, medulloblastoma, glioma, and AML. Identification of therapy-resistant patients early in their treatment regimen can lead to a change in therapy in order to achieve a more successful outcome. One embodiment of the present invention is directed to a method for diagnosing cancer or predicting cancer-therapy outcome by detecting the expression levels of multiple markers in the same cell at the same time, and scoring their expression as being above a certain threshold, wherein the markers are from a particular pathway related to cancer, with the score being indicative or a cancer diagnosis or a prognosis for cancer-therapy failure. This method can be used to diagnose cancer or predict cancer-therapy outcomes for a variety of cancers. The markers can come from any pathway involved in the regulation of cancer, including specifically the PcG pathway and the “stemness” pathway. The markers can be mRNA, microRNA, DNA, or protein.
Owner:ORDWAY RES INST
Chimeric immunoreceptor useful in treating human cancers
InactiveUS20090257994A1Negligible toxicityPotent and selectiveBiocidePeptide/protein ingredientsIntracellular signallingMalignancy
The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin / paracrine cytokine systems utilized by human malignancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.
Owner:CITY OF HOPE
Phospholipid ether analogs as cancer treatment agents and methods thereof
ActiveUS20070020178A1Improve the level ofX-ray constrast preparationsRadioactive preparation carriersMelanomaLymphatic Spread
The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.
Owner:CELLECTAR
Therapeutic morpholino-substituted compounds
Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.
Owner:ASTRAZENECA AB
Chimeric immunoreceptor useful in treating human cancers
InactiveUS20060067920A1Negligible toxicityPotent and selectiveBiocideAntibody mimetics/scaffoldsIntracellular signallingAutocrine paracrine
The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin / paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.
Owner:CITY OF HOPE
Gene knockout vector and zebra fish glioma model thereof
The invention provides a gene knockout vector and a zebra fish glioma model thereof. The gene knockout vector is obtained by connecting a target sequence to plasmids capable of expressing CRISPR-Cas9gene editing system related enzymes, and the target gene is a p53, Rb1 or Nf1 gene. The CRISPR / CAS9 technology is utilized for performing targeted knockout of rb1, nf1 and tp53 genes, an established transgene-induced malignant glioma zebra fish model can observe occurrence of malignant gliomas, tumor-induced angiogenesis and glioma stem cell generating processes through real-time fluorescence, andthe difference of pathogenesis of gliomas under different genetic background conditions is studied through the molecular biotechnology.
Owner:SHANTOU UNIV MEDICAL COLLEGE
Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
InactiveUS20100273808A1High drug loadingOrganic active ingredientsNervous disorderCell survivalCarboxylic acid
This invention provides a compound of formula (I):or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; and the use of said compound, or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof, for the treatment of patients suffering from or subject to diseases, disorders or conditions involving cell survival, proliferation, and migration, including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer, (e.g., AML and malignant glioma)glomerulosclerosis, fibrotic disease and inflammation.
![Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders](https://images-eureka.patsnap.com/patent_img/066cbb96-2b5e-425b-b3cc-1a9460205ec7/US20100273808A1-20101028-D00001.png "Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders")
![Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders](https://images-eureka.patsnap.com/patent_img/066cbb96-2b5e-425b-b3cc-1a9460205ec7/US20100273808A1-20101028-D00002.png "Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders")
![Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders](https://images-eureka.patsnap.com/patent_img/066cbb96-2b5e-425b-b3cc-1a9460205ec7/US20100273808A1-20101028-D00003.png "Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders")
Owner:MILLENNIUM PHARMA INC
An anti-tumor compound and its preparation method, application, and pharmaceutical compositions
InactiveCN102924507AHighly directional (targeted) selectionOrganic active ingredientsGroup 5/15 element organic compoundsDiseaseEster prodrug
The present invention discloses an anti-tumor compound and its preparation method,application, and pharmaceutical compositions. The anti-tumor compound is a 4 - nitro-substituted benzyl group ifosfamide ester prodrug thereof, or pharmaceuticallysalt, or solvate thereof of the structure of formula I. The structure of formula I. The present invention has the following advantage of being used for the treatment or prevention of mammalian tumor-related diseases, such as leukemia, hemangioma, glioma, Kaposi's sarcoma, ovarian cancer, breast cancer, lung cancer, pancreatic cancer, lymphoma, prostate, colon and skin tumors and their complications.
Owner:ANHUI SIWEI PHARMA
Engraftable neural progenitor and stem cells for brain tumor therapy
One of the impediments to the treatment of some human brain tumors (e.g. gliomas) has been the degree to which they expand, migrate widely, and infiltrate normal tissue. We demonstrate that a clone of multipotent neural progenitor stem cells, when implanted into an experimental glioma, will migrate along with and distribute themselves throughout the tumor in juxtaposition to widely expanding and aggressively advancing tumor cells, while continuing to express a foreign reporter gene. Furthermore, drawn somewhat by the degenerative environment created just beyond the infiltrating tumor edge, the neural progenitor cells migrate slightly beyond and surround the invading tumor border. When implanted at a distant sight from the tumor bed (e.g., into normal tissue, into the contralateral hemisphere, into the lateral ventricles) the donor neural progenitor / stem cells will migrate through normal tissue and specifically target the tumor cells. These results suggest the adjunctive use of neural progenitor / stem cells as a novel, effective delivery vehicle for helping to target therapeutic genes and vectors to invasive brain tumors that have been refractory to treatment.
Owner:CHILDRENS MEDICAL CENT CORP +2
Methods of using CD44 fusion proteins to treat cancer
Pharmaceutical compositions and methods for treating cancer using CD44 antagonists are disclosed. In certain aspects, these pharmaceutical compositions and methods include treating a mammal having a cancer, such as glioma, colon cancer, breast cancer, prostate cancer, ovarian cancer, lung cancer, renal cell carcinoma, gastric cancer, esophageal cancer, head cancer, neck cancer, pancreatic cancer, or melanoma, with a CD44 fusion protein. These CD44 fusion proteins include CD44-Fc fusions and can be used to detect hyaluronan.
Owner:CENT HOSPITALER UNIV VAUDOIS UNIV OF LAUSANNE +1
Diagnosis and treatment of tumors
InactiveUS20070237714A1Stability and safety and efficacy and lack of immunogenicityImprove visualizationOrganic active ingredientsPeptide/protein ingredientsAbnormal tissue growthNeuroectoderm
The present invention is directed to methods and compositions for the treatment and diagnosis of neuroectodermally-derived tumors, such as gliomas. The inventive methods of treatment generally include local (e.g., intracavitary) administration of a chloroxotoxin moiety conjugated to a cytotoxic moiety to a patient. Also provided are diagnostic methods for screening neoplastic neuroectodermal tumors.
Owner:MORPHOTEX INC
Compositions and Methods for Treating Glioblastoma GBM
Methods of treating a malignant glioma in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a viral vector comprising: (i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c), said first polynucleotide sequence comprising SEQ ID NOs: 2 and 3; and (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter.
Owner:VASCULAR BIOGENICS
Anti-tumoural effects of cannabinoid combinations
ActiveUS8632825B2Prevent induced cellBiocideHydroxy compound active ingredientsGlioblastomaCannabinoid
The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumor, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).
Owner:GW PHARMA LTD
Cannabinoids in combination with non-cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents)
The invention relates to the use of one or more cannabinoids, particularly THC and / or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). The non-cannabinoid chemotherapeutic agent may be a selective estrogen receptor modulator or an alkylating agent.
Owner:GW PHARMA LTD
Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class i or class ii molecules for vaccine
ActiveUS20100158929A1Good adjuvant effectIncrease heightPeptide/protein ingredientsMetabolism disorderKidney cancerGlioblastoma
The present invention relates to novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules as vaccines for the use in immunotherapeutic methods. In particular, the present invention relates to formulations for the immunotherapy of cancer, in particular renal and brain cancer, in particular glioma, especially glioblastoma cancer. The present invention furthermore relates to vaccine compositions for eliciting anti-tumour immune responses.
Owner:IMMATICS BIOTECHNOLOGIES GMBH
Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
ActiveUS20070167375A1High magnitudeImprove CTL reactivityNervous disorderPeptide/protein ingredientsEpitopeCytotoxicity
The invention provides a peptide derived from the interleukin-13 receptor α2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.
Owner:UNIVERSITY OF PITTSBURGH
Use Of Cox-2 Inhibitor to Prevent T-Cell Anergy Induced By Dendritic Cell Therapy
InactiveUS20080199484A1Good treatment effectOrganic active ingredientsSnake antigen ingredientsT lymphocyteWilms' tumor
The present invention relates to a method and combination therapy useful in the treatment of cancer. More specifically, the invention relates to the use of COX-2 inhibitors in combination with a therapeutic dendritic cell vaccine for treating cancer. The COX-2 inhibitors of the present invention are believed to inhibit the enzymatic activity of prostaglandineE2 (PGE2); thereby preventing COX-2 overexpressing tumors from evading immune surveillance by antigen-specific cytotoxic T lymphocytes (CTLs). COX-2 inhibitors are believed to suppress PGE2 that COX-2 overexpressing glioma produce, allowing tumor-infiltrating DCs to polarize Th cells toward Th-subset-1 (Th1).
Owner:CEDARS SINAI MEDICAL CENT
Tumor suppressor designated TS10q23.3
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Methods
The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.
Owner:AEROMICS
Method of diagnosing and treating gliomas
InactiveUS6870029B2Reduce current amplitudeSmall sizePeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsGlioblastomaMonoclonal antibody
The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.
Owner:UAB RES FOUND
Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
Owner:UNIVERSITY OF PITTSBURGH
Pep-1 peptide modified gliomas targeted nano drug delivery system and preparation method thereof
InactiveCN103655517AHigh fluorescence intensityIncrease savingsOrganic active ingredientsMacromolecular non-active ingredientsMonomethoxypolyethylene glycolTherapeutic effect
The invention discloses a Pep-1 peptide modified gliomas targeted nano drug delivery system and a preparation method thereof. The nano drug delivery system comprises polymer nano particles prepared by using an amphiphilic block copolymer (Pep-PEG-PLGA) as a carrier material, paclitaxel wrapped and carried by the polymer nano particles, and modified ligand Pep-1 polypeptide on the surfaces of the polymer nano particles. The amphiphilic block copolymer (Pep-PEG-PLGA) is composed of Male-PEG-PLGA and MePEG-PLGA, Pep-1 is adopted as a molecule with targeting function, the amphiphilic block copolymer PEG-PLGA is taken as a carrier material, the Pep-1 polypeptide is modified on the carrier material via covalent binding, and gliomas targeted polymer nano particles are prepared. According to the Pep-1 peptide modified gliomas targeted nano drug delivery system, gliomas targeting can be voluntarily performed, and the uptaking and accumulation of an anti-tumour drug in the gliomas part can be improved, as a result, the gliomas therapeutic effect is improved.
Owner:NANJING MEDICAL UNIV
Chimeric immunoreceptor useful in treating human cancers
InactiveUS20110223129A1Negligible toxicityPotent and selectivePeptide/protein ingredientsAntibody mimetics/scaffoldsIntracellular signallingImmune receptor
Owner:CITY OF HOPE
Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
InactiveUS20050287148A1Reduce riskVirusesAntibody mimetics/scaffoldsSmall-cell carcinomaTolerability
The present invention relates to monoclonal antibody 1A7. This is an anti-idiotype produced by immunizing with an antibody specific for ganglioside GD2, and identifying a hybridoma secreting antibody with immunogenic potential in a multi-step screening process. Also disclosed are polynucleotide and polypeptide derivatives based on 1A7, including single chain variable region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the 1A7 antibody overcomes immune tolerance and induces an immune response against GD2, which comprises a combination of anti-GD2 antibody and GD2-specific T cells. The invention further provides methods for treating a disease associated with altered GD2 expression, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treat with a composition of this invention in hopes of reducing the risk of recurrence.
Owner:UNIV OF KENTUCKY RES FOUND
Prognostic and diagnostic method for disease therapy
Owner:ORDWAY RES INST
Gene sets for glioma classification
The present invention provides a number of gene markers whose expression is altered in various gliomas. In particular, by examining the expression these markers, one can accurately classify a glioma as glioblastoma multiforme (GM), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO) or oligodendroglioma (OL). The diagnosis may be performed on nucleic acids, for example, using a DNA microarray, or on protein, for example, using immunologic means. Also disclosed are methods of therapy.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com